Temporal exposure to chondrogenic factors modulates human mesenchymal stem cell chondrogenesis in hydrogels.
Tissue engineering utilizes scaffolds containing chondrogenic cells to promote cartilage development at a clinically relevant scale, yet there remains a limited understanding of the optimal conditions for inducing differentiation and matrix production. We investigated how cell density and temporal exposure to chondrogenic factors impacted chondrogenesis of human mesenchymal stem cells (hMSCs) encapsulated in poly(ethylene glycol) diacrylate hydrogels. We found maximal proteoglycan and collagen production in constructs seeded between 10 and 25 × 10(6) cells/mL. Matrix deposition was significantly less per cell in constructs seeded at either higher or lower densities, indicating that paracrine communications may remain important despite loss of direct cell-cell contact. In vitro chondrogenesis of hMSCs was first accomplished using pellet cultures and a defined medium containing transforming growth factor (TGF)-β1 and dexamethasone. The differentiation of hMSCs in hydrogels also required initial exposure to TGF-β1, with no chondrogenic matrix produced in its absence. If TGF-β1 was initially included for at least 7 days, its removal impacted collagen production per cell but also lead to an increase in cell number, such that total collagen deposition was equivalent to controls when TGF-β1 was included for at least 3 weeks. Further, proteoglycan content per construct was higher at 6 weeks after removal of TGF-β1 at any time. In contrast to TGF-β1, dexamethasone was not required for chondrogenesis of hMSCs in hydrogels: there was no difference in matrix deposition between hydrogels cultured with or without dexamethasone. Further, without dexamethasone, SOX9 gene expression was higher during early chondrogenesis and there was a significant reduction in collagen I deposition, suggesting that a more hyaline cartilage phenotype is achieved without dexamethasone. Collagen content at 6 weeks was lower if dexamethasone was excluded after the first 7 days, but was equivalent to control if dexamethasone was included for 2 weeks or longer. Proteoglycan deposition was unaffected by dexamethasone exclusion. These results indicate that modulating exposure to TGF-β1 is beneficial for cell survival/proliferation and matrix production from hMSCs in hydrogels, and that not only is dexamethasone dispensable but also its exclusion may be advantageous for forming hyaline cartilage.
Buxton
Amanda N
AN
Department of Orthopaedics and Rehabilitation, Oregon Health and Science University, Portland, Oregon, USA.
Bahney
Chelsea S
CS
Yoo
Jung U
JU
Johnstone
Brian
B
D000328:Adult; D000368:Aged; D018929:Cell Culture Techniques / Q000379:methods; D002478:Cells, Cultured; D019902:Chondrocytes / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D020219:Chondrogenesis / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage*; D008297:Male; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D008875:Middle Aged; D013997:Time Factors; D023822:Tissue Engineering / Q000379:methods*; D055815:Young Adult
D036341:Intercellular Signaling Peptides and Proteins
J Cell Physiol. 2009 Apr;219(1):219-26
19107842
Dev Biol. 2008 Apr 1;316(1):62-73
18295755
Histol Histopathol. 2002 Oct;17(4):1239-67
12371151
Arthritis Rheum. 2008 Sep 15;59(9):1207-13
18759314
Arthritis Rheum. 2006 Oct;54(10):3254-66
17009260
Cell Differ. 1975 Jun;4(3):131-7
167985
Science. 1999 Apr 2;284(5411):143-7
10102814
Biochim Biophys Acta. 1986 Sep 4;883(2):173-7
3091074
Curr Top Dev Biol. 2007;79:1-36
17498545
Cell Differ. 1982 Jun;11(4):245-51
7116459
Tissue Eng Part B Rev. 2008 Jun;14(2):149-65
18498217
Exp Cell Res. 1998 Jan 10;238(1):265-72
9457080
Dev Biol. 1982 Nov;94(1):259-64
6759202
Biomaterials. 2001 Mar;22(5):439-44
11214754
Tissue Eng Part A. 2010 Feb;16(2):523-33
19715387
J Cell Physiol. 2010 Jan;222(1):23-32
19725073
J Anat. 1971 Sep;109(Pt 3):411-21
5153801
Nat Biotechnol. 2005 Jan;23(1):47-55
15637621
Endocrinology. 1994 Jan;134(1):277-86
8275945
J Biol Chem. 2003 Oct 17;278(42):41227-36
12893825
J Bone Joint Surg Am. 1998 Dec;80(12):1745-57
9875932
Expert Opin Biol Ther. 2001 Nov;1(6):915-21
11728225
Tissue Eng. 2003 Aug;9(4):679-88
13678446
In Vitro Cell Dev Biol Anim. 2002 Sep;38(8):457-66
12605540
J Orthop Res. 2002 May;20(3):562-74
12038632
J Biol Chem. 2001 Apr 27;276(17):14466-73
11278290
Adv Anat Embryol Cell Biol. 2008;200:1 p following vi, 1-84
18841755
J Bone Joint Surg Am. 2002 May;84(5):793-9
12004023
Bone. 2003 Jul;33(1):1-13
12919695
J Anat. 2000 Nov;197 Pt 4:659-79
11197539
Development. 1997 Jul;124(13):2659-70
9217007
Stem Cells. 2006 Jun;24(6):1487-95
16469821
Injury. 2008 Apr;39 Suppl 1:S58-65
18313473
Z Rheumatol. 1991 Sep-Oct;50(5):304-12
1776367
Tissue Eng. 2007 May;13(5):1025-34
17417949
Osteoarthritis Cartilage. 2006 Feb;14(2):179-89
16257243
Clin Orthop Relat Res. 1994 Apr;(301):271-80
8156688
Tissue Eng. 2007 Oct;13(10):2369-85
17658993
J Cell Biol. 1997 Oct 20;139(2):541-52
9334355
J Bone Joint Surg Am. 2010 Apr;92(4):994-1009
20360528
Tissue Eng. 2003 Dec;9(6):1301-12
14670117
Tissue Eng. 2007 Oct;13(10):2549-60
17655489
Int J Dev Biol. 1999 Jan;43(1):59-67
10213083
J Cell Biol. 1984 Jul;99(1 Pt 1):115-23
6539780
Clin Orthop Relat Res. 2004 Oct;(427 Suppl):S69-77
15480079